A Pharmacokinetic Study of SHR8554 Injection in the Population With Renal Insufficiency and Healthy Participants

Inclusion Criteria: 1. Able and willing to provide a written informed consent; 2. The estimated glomerular filtration rate (eGFR) of subjects in groups must meet the corresponding standards; 3. Male or female; 4. with a body mass index (BMI) between 18.0 and 28.0 kg/m2. Exclusion Criteria: 1. History of clinically significant allergies, known allergy to SHR8554, or any other structural analogs; 2. Subjects with positive tests for infectious diseases; 3. Pregnancy or lactation women, or a fertility male or female is not willing to contraception during test; 4. Unable to tolerate venipunctures or have a history of fainting needles and blood; 5. Historic abuse of alcoholic beverages; 6. Smoke ≥ 10 cigarettes per day within 3 months prior to the study; 7. History of drug abuse; 8. Diseases with abnormal clinical manifestations that occurred before screening or are currently occurring and need to be excluded for normal renal function group; 9. Vital signs, physical examination, 12-lead electrocardiogram, or laboratory examination deemed clinically significant by the investigator for normal renal function group; 10. History of renal transplantation and/or requirement for renal dialysis treatment during the study period for severe renal function group; 11. Urinary incontinence or anuria (e.g., \< 100 mL/day) for severe renal function group; 12. Other reasons that the investigator consider it inappropriate to participate in the trial.